Triple-negative breast cancer (TNBC), one the most aggressive forms of the disease, doesn’t respond well to standard treatments. The U.S. Food and Drug Administration (FDA) recently approved the immunotherapy pembrolizumab (Keytruda®) for the treatment of early-stage TNBC. Sylvia Adams, MD, professor in the Department of Medicine and director of the Breast Cancer Center at NYU Langone Health’s Perlmutter Cancer Center, who was among the investigators involved in the pembrolizumab clinical trials, notes that preventing metastatic TNBC, which is difficult to treat, is crucial.

“It changes the standard of care and should be discussed with all patients who are diagnosed with stage 2 to 3 TNBC,” Dr. Adams says. “Yes, it’s a game changer, though there is much more to be learned.”

Read more from SurvivorNet.